Claims for Patent: 10,100,109

Summary for Patent: 10,100,109

Title:	Anti-activin A antibodies and uses thereof
Abstract:	The disclosure provides compositions and methods relating to or derived from anti-activin A binding proteins, including antibodies. In particular embodiments, the disclosure provides fully human, humanized, and chimeric anti-activin A antibodies that bind human activin A, activin A-binding fragments and derivatives of such antibodies, and activin A-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having activin A-related disorders or conditions including cachexia related to gonadal cancer, other cancers, rheumatoid arthritis, and other diseases.
Inventor(s):	Huiquan Han, Qing Chen, Keith Soo-Nyung Kwak, Xiaolan Zhou
Assignee:	Amgen Inc
Application Number:	US15/346,617

Details for Patent 10,100,109

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	ACTEMRA	tocilizumab	Injection	125276	January 08, 2010		2036-11-08

International Patent Family for US Patent 10,100,109

Country	Patent Number	Estimated Expiration
Argentina	062703
Argentina	065611
Argentina	074397